AbbVie's Latest Clinical Trial for Alopecia Areata Shows Positive Results | iPharmaCenter

AbbVie announced positive topline results from its second Phase 3 UP-AA trial for the alopecia areata treatment, Rinvoq (upadacitinib). The study showed that both the 15 mg and 30 mg doses of the drug met the primary endpoint, leading to significant scalp hair regrowth in a large percentage of patients after 24 weeks.

A key finding from the trial was the significant difference in outcomes compared to placebo. At week 24, 45.2% of patients on the 15 mg dose and 55.0% of those on the 30 mg dose achieved 80% or more scalp hair coverage, while only 1.5% of patients in the placebo group reached this milestone.

Find the list of top pharmaceutical companies by revenues in 2025

The trial also successfully met key secondary goals, including a higher percentage of patients reaching 90% or more scalp coverage. Specifically, 35.2% on the 15 mg dose and 45.8% on the 30 mg dose achieved this, compared to just 0.7% of patients on placebo. The trial also showed improvements in eyebrow and eyelash hair.

Also read: FDA Approves GSK’s Nucala for COPD Patients with Eosinophilic Inflammation

These findings are consistent with the first parallel study and highlight the potential of upadacitinib to provide meaningful hair regrowth for those living with the psychosocial burden of alopecia areata. The company noted that the safety profile observed in this trial was consistent with the known safety of RINVOQ in its approved uses, with no new safety signals identified.